Trial Profile
Genetic Epidemiology of Responses to Antihypertensives
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Candesartan cilexetil (Primary) ; Hydrochlorothiazide (Primary)
- Indications Essential hypertension
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms GERA
- 29 Jan 2013 New trial record